Led by researchers at the University of Laval in Canada, the study found that mice with increased levels of cannabinoid ...

Montreal-based Inversago Pharma is developing a portfolio of peripherally-acting cannabinoid receptor-1 (CB1) inverse agonists, including its lead candidate INV-101, in development for the ...

Dr. Chris Twitty, Chief Scientific Officer of Skye, said, “These data demonstrate for the first time how nimacimab’s allosteric binding to the CB1 receptor is differentiated from the small molecules ...

Agonists of the type 1 cannabinoid receptor (CB1) show promise as alternative analgesics but are still limited by side effects and tolerance. Reporting in Nature, Rangari et al. apply computation ...